# Cediranib

Source: https://onco.cc/drugs/cediranib/  
OnCo record `cediranib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cediranib is a tablet that blocks the blood-vessel growth signal VEGF. In alveolar soft part sarcoma, a rare very vascular sarcoma that ignores chemotherapy, a randomised trial showed it shrinks tumours and delays progression, although it was never licensed.

## Summary

Cediranib (AZD2171) is AstraZeneca's oral inhibitor of VEGFR-1, -2 and -3. It was tested widely, including the ICON6 trial in relapsed ovarian cancer, but never gained approval. Its clearest activity is in alveolar soft part sarcoma: a National Cancer Institute phase 2 showed responses in a third of patients, and the randomised, placebo-controlled CASPS trial (Lancet Oncology, 2019) found a greater reduction in tumour size at 24 weeks and longer progression-free survival than placebo.

Cediranib remains an investigational drug available in some countries through trials or special access; other VEGFR inhibitors such as sunitinib, pazopanib and anlotinib, and checkpoint inhibitors such as atezolizumab, are used in practice. The alveolar soft part sarcoma page names it among the VEGFR-directed drugs that are active in the disease.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-17
- Also known as: AZD2171; Recentin
- Tags: subtype-drugs-wave
- Code: AZD2171
- Modality: Oral VEGFR 1-3 tyrosine kinase inhibitor
- Mechanism: A potent inhibitor of all three VEGF receptors, with activity against PDGFR and KIT, that blocks tumour angiogenesis; alveolar soft part sarcoma is highly vascular and driven by the ASPSCR1-TFE3 fusion, which upregulates angiogenic genes.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cediranib
- Wikipedia: https://en.wikipedia.org/wiki/Cediranib

## Connected records

- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Pazopanib](https://onco.cc/drugs/pazopanib/), [Sunitinib](https://onco.cc/drugs/sunitinib/)
- cancers: [Alveolar soft part sarcoma](https://onco.cc/cancers/alveolar-soft-part-sarcoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/cediranib.json